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Abstract
Bacterial vaginosis (BV) is a common yet poorly understood vaginal condition that has 
become a major focus of HIV transmission and immunology research. Varied 
terminologies are used by clinicians and researchers to describe microbial communities 
that reside in the female reproductive tract, which is driven in part by microbial genetic 
and metabolic complexity, evolving diagnostic and molecular techniques, and 
multidisciplinary perspectives of clinicians, epidemiologists, microbiologists, and 
immunologists who all appreciate the scientific importance of understanding 
mechanisms that underlie “BV”. This Perspectives article aims to clarify the varied terms 
used to describe the cervicovaginal microbiota and its “non-optimal” state, under the 
overarching term of BV. The ultimate goal is to move toward language standardization 
in future literature that facilitates a better understanding of the impact of BV on female 
reproductive tract immunology and risk of sexually transmitted infections including HIV.
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Introduction
Bacteria are now recognized to play important immunological roles at all mucosal 
surfaces, and the female reproductive tract (FRT) is no exception.1 The entirety of 
“optimal” microbial communities associated with a mucosal site (i.e. the microbiota) is 
an important contributor to the effectiveness of the host mucosal barrier against 
infection.2 This is in contrast to “non-optimal” microbial communities that are associated 
with the disruption of important physiological roles of bacteria at the mucosa.1  An 
example of non-optimal microbiota is bacterial vaginosis (BV) a common vaginal 
condition in women of reproductive-age associated with adverse urogenital and 
reproductive health outcomes including an increased risk of HIV acquisition.3-7 BV 
affects 29% of women in the United States and 52% of women in sub-Saharan Africa, 
where HIV is also highly prevalent.8
BV is commonly diagnosed by clinicians using Amsel’s criteria9, defined here as “Amsel-
BV”, a ‘vaginal discharge syndrome’  where at least three out of four diagnostic criteria 
need to be met (Box 1).  While women with BV can present with a vaginal discharge, 
BV is not typically associated with redness, swelling or pain seen with “overt” 
inflammation10, which is why it is referred to as “vaginosis” rather than “vaginitis”.  
However, BV is associated with “subclinical” genital inflammation, as determined by an 
increase in pro-inflammatory cytokines and chemokines10-16 associated with increased 
HIV risk.17-19  A second common method used to diagnose BV is by Nugent score, 
defined here as “Nugent-BV” (Box 1)20. The Nugent score captures bacterial 
morphotypes on a Gram stain, differentiating Lactobacillus-dominated bacterial 
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communities from the presence of small Gram-variable rods (Gardnerella 
vaginalis morphotypes) and curved Gram-variable rods (Mobiluncus spp. 
morphotypes)5, which is an oversimplification of the actual ecology of BV.21,22
Nugent scoring has been used widely, particularly in epidemiology research, to define 
BV in large cohort studies, correlating BV to a wide range of adverse health 
outcomes.18,19,23  A proportion of women with Nugent-BV are clinically asymptomatic 
(“asymptomatic BV”).  Nugent-BV can be sustained or transient, the latter representing 
a temporary shift in the vaginal microbiota mediated by intrinsic (menses) or extrinsic 
(sex) factors24, which may or may not be associated with increased HIV risk. Some 
women with Amsel-BV may also not present with symptoms; while this may be 
uncommon for women presenting to a clinic, population-based Amsel screening will 
identify asymptomatic Amsel-BV positive women.  The presence of signs and symptoms 
of BV vary widely based on the perception of women and clinicians, complicating its 
diagnostic usefulness. Thus, BV that is diagnosed by either Amsel or Nugent methods 
can be further delineated as either “asymptomatic” or “symptomatic”. 
While clinical manifestations of BV are important for patient care, it is now clear with 
advances in DNA sequencing technology that a broader range of non-optimal 
cervicovaginal microbiota have relevance for adverse sexual and reproductive health 
outcomes. CervicovVaginal microbiota are genetically and ecologically complex, diverse 
and dynamic.24 This combined with its health implications has made it a “hot topic” for 
molecular microbiologists. Several immunological and clinical associations of various 
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cervicovaginal bacterial communities have now been characterized using molecular 
methods; these “non-optimal” microbiota broadly overlap with BV defined by other 
methods, but are distinct and we have termed these as “Molecular-BV” (Box 1).  As 
subtle differences between methods come to light, “Molecular-BV” should be further 
subdivided into terms that incorporate the specific molecular method (Box 1). One 
common method for microbiota characterization in recent literature is deep sequencing 
of the 16S rRNA gene. This method has been termed as a “broad-range PCR” method 
that measures the relative abundance of bacteria taxa without pre-conceived knowledge 
of the bacteria that are present.25-28 We propose that “non-optimal” microbial 
communities defined by this technique be designated as “Seq-BV”, which would also 
incorporate whole genome shotgun-sequencing approaches.  A second method is 
taxon-specific quantitative PCR (qPCR) that quantifies the absolute abundance of pre-
determined taxa26,29, while not including others. We propose that “non-optimal” taxa are 
designated as ‘qPCR-BV’.  Metaproteomic analysis of cervicovaginal samples has also 
been employed to study the cervicovaginal environment, including bacterial 
composition, which has led to “optimal” and “non-optimal” bacterial community 
classifications, where the latter could be designated as Prot-BV.30-32
The concept of “Molecular-BV”, as defined currently in research settings, is intended to 
be an “overarching” term to describe non-optimal cervicovaginal microbiota 
characterized by molecular methods. This is not to suggest that it is not clinically 
relevant. An FDA approved molecular diagnostic test for BV is being used in the US.33,34  
In addition, Molecular-BV has been associated with genital inflammation and/or adverse 
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sexual and reproductive health outcomes such as increased HIV risk17,29, and therefore 
is prognostic for clinical outcomes. Understanding this distinction may enable better 
comparisons to studies where BV has been determined using Amsel’s criteria or Nugent 
score.18,19
Molecular-BV bacterial communities are depleted of Lactobacillus spp., with a high 
relative abundance or load of facultative and/or obligate anaerobes (see Box 1, and 
Table 1 for microbial communities typical of Molecular-BV). 12,17,25-27  These 
communities are usually “highly diverse”  (i.e. high species richness or polymicrobial) 
and show “evenness” (i.e. not dominated by particular species), although they can be 
dominated by the one species. Examples of Seq-BV include microbiota commonly 
referred to as cervicotypes 3 (CT3) and 4 (CT4), which proportionally are depleted of 
Lactobacillus spp. and predominately contain Gardnerella vaginalis or an increase in a 
mixture of diverse anaerobes comprising Prevotella, Gardnerella, BVAB1, Sneathia and 
Megasphera spp., respectively.11,17  Examples of qPCR-BV include additional taxa 
shown to have a concentration-dependent association with genital inflammation and/or 
increased risk of HIV acquisition e.g. Gemella asaccharolytica and Eggerthella species 
type I.29
Techniques used to define Molecular-BV have demonstrated that an even larger 
proportion of asymptomatic women may be at risk of sub-clinical cervicovaginal 
inflammation and increased risk of acquiring sexually transmitted infections (STI) 
including HIV.17,29  However, these overlapping yet distinct approaches for defining BV 
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have led to some confusion for researchers in the field. A patchwork of terms describing 
BV and cervicovaginal microbiota continues to evolve as studies employ increasingly 
complex molecular measurements to better capture aspects of the microbiota that go 
beyond clinical or microscopic criteria by using bacterial relative or absolute bacterial 
abundances. This Perspectives article attempts to capture the heterogeneous 
terminology generated from this multidisciplinary research effort geared at 
understanding the intricate relationships between “BV”, as defined by Amsel, Nugent 
and molecular methods, cervicovaginal inflammation, and the risk of HIV/STIs. 
While here we focus on BV, it is important to note that there are additional forms of 
“non-optimal” cervicovaginal microbiota associated with vulvovaginal candidiasis (VVC) 
caused by Candida spp., and desquamative vaginitis or aerobic vaginitis caused by 
pathobionts Proteobacteria, Streptococci, Staphylococci or Enterococci spp.35,36  These 
microbes and STIs other than HIV are clinically relevant and are associated with genital 
inflammation that can increase HIV risk (Figure 1), and are therefore important when 
considering sources of inflammation in the cervicovaginal mucosa, but do not feature in 
the definitions of BV, which is the current focus of this Perspectives article.35  An update 
on this topic is planned in a report on the 2018 Keystone Symposia on the Role of the 
Genital Tract Microbiome in Sexual and Reproductive Health.
Partial overlap between Amsel-BV, Nugent-BV, and Molecular-BV
Current evidence supports that only a minority of BV is symptomatic. Molecular-BV/Seq-
BV, which categorizes microbiota into bacterial community types (Table 1), tends to 
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correlate with vaginal pH and not with other Amsel criteria, such as clue cells and whiff 
test.28,37  Similarly, although Seq-BV correlates with Nugent-BV (Figure 2), the overlap 
is incomplete.17,22,25  The majority of women who have an intermediate Nugent score 
(defined in Box 1) also have Seq-BV (e.g. CT3, and CT4 and CST-IV)11,17,22, indicating 
an association with adverse health outcomes.17  We propose that data from primarily 
clinical (Amsel), microscopic (Nugent) and molecular evaluation of BV fit into an 
“iceberg” concept of a clinical/sub-clinical condition (Figure 2).  Amsel-BV is at the top of 
the iceberg, usually capturing clinically apparent non-optimal vaginal microbiota, while 
both Nugent-BV and Molecular-BV include additional microbial states that can be sub-
clinical (e.g. asymptomatic) but still clinically relevant for infection and/or health risk. It is 
worth noting that some Amsel positive diagnoses may not be Nugent positive due to 
either subjectivity of the Amsel criteria (e.g. vaginal discharge, odor) or perhaps 
differences in the ability of these tests to detect BV-associated with biofilm versus 
planktonic BV, although these cases are uncommon.
Non-optimal cervicovaginal microbiota, genital inflammation, and HIV acquisition 
risk
Meta-analyses clearly demonstrate that women with Nugent-BV and/or Amsel-BV have 
an increased risk of acquiring HIV.18,19 A meta-analysis by Atashili and colleagues 
(2008) of twenty-three studies including 30,739 women, reported a relative risk of 1.61 
(95% confidence interval 1.21 - 2.13) for HIV acquisition in women with Nugent-BV. 
Subsequently, an individual patient meta-analysis by Low and colleagues (2011) 
reported that Nugent-BV, measured at the seronegative visit before HIV diagnosis, was 
Page 12 of 40
Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801
AIDS Research and Human Retroviruses
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only; Not for Distribution
12
associated with an adjusted hazard ratio of 1.53 (95% CI 1.24-1.89) for HIV acquisition 
risk 19. This study also demonstrated an elevated susceptibility to HIV (aHR 1.41, 95% 
CI 1.12-1.79) in women with intermediate Nugent scores19, suggesting that any Nugent 
score >3 may be a risk factor for HIV.  On the basis of more recent molecular studies, a 
large proportion of these women would be expected to have Molecular-BV.11,17,22
Nugent-BV has repeatedly been associated with genital inflammation; in particular, pro-
inflammatory cytokines are typically up-regulated whereas chemokines show no 
association, are up-regulated (i.e. IL-8) or down-regulated.10,14-16  This cytokine-
chemokine distinction is likely due to the observation that BV is microbiologically 
multifaceted, and specific combinations of bacterial species may result in different host 
responses.28 The host response to the same bacterial communities could also vary 
between individuals, even though no studies have evaluated this specific question. In 
addition, some differences could be accounted for by methodological differences in 
sampling and measuring immune mediators in the genital tract.10
Molecular-BV has often been associated with both genital inflammation11-13 and an 
increased risk of HIV acquisition.17,29  A prospective study in South Africa reported that 
young women colonised with a highly diverse community (CT4), had a 4.4-fold (95% CI: 
1.17-16.61) increased risk of acquiring HIV compared to women with L. cr spatus-
dominant microbiota.17  Presence of the G. vaginalis-dominated (CT3) cervicotype 
demonstrated a trend towards elevated HIV risk although it did not reach statistical 
significance after adjusting for the presence of chlamydia.17 The L. iners- dominated 
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(CT2) cervicotype was not significantly associated with increased HIV risk.17   In this 
cohort, women with CT4 also had the greatest genital inflammation measured by levels 
of pro-inflammatory cytokines and chemokines, compared to women with L. crispatus-
dominated microbiota, and followed by G. vaginalis-dominated and L. iners-dominated 
microbiota.11  Another nested case-control study in African women showed that vaginal 
bacterial diversity and several BV-associated bacterial species, including Parvimonas 
species types 1 and 2, Gemella asaccharolytica, Mycoplasma hominis, 
Leptotrichia/Sneathia, Eggerthella species type 1, and Megasphaera species, were 
significantly associated with higher risk of HIV acquisition.29
Several studies have demonstrated that elevated genital inflammation is associated with 
an increase in activated HIV target cells in the cervix11,17,38, consistent with elevated HIV 
risk.17 However, not all studies have found an association between cervicovaginal 
bacterial communities and the frequency of CD4+ and CCR5+ activated or proliferating 
HIV target cells in the cervix12,39 suggesting differences between geographic or ethnic 
populations.  Alternatively, there could be other mechanisms by which non-optimal 
cervicovaginal microbiota increase HIV risk, such as disruption of epithelial barrier 
integrity.30-32,38
Effect Sizes for HIV risk determined by Nugent/Amsel-BV versus Molecular-BV 
The effect sizes for Nugent-BV/Amsel-BV on HIV risk are typically smaller, i.e. 60% 
increased risk18,19 compared to the effect size from Seq-BV on HIV risk (i.e. >4-fold).17,28 
However, the latter was only from two studies, with modest numbers of women 
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colonised with L. crispatus-dominated cerviocovaginal microbiota, and needs to be 
confirmed.17 The large sample size (>30,000 individuals) evaluated in the BV meta-
analysis could contribute to and explain the smaller effect sizes. The meta-analysis of 
Nugent-BV is also adjusted for potential confounders such as VVC and sexual 
behaviours, although these are incompletely controlled for in studies relying on 
Molecular-BV.17,29 
While Nugent and Amsel are useful tools for epidemiological and clinical studies they 
could be thought of as less sensitive, i.e., underestimating the types of microbiota that 
put a woman at risk for HIV, compared to molecular evaluation of cervicovaginal 
microbiota, at least in research settings (Figure 2).  Nugent and molecular techniques 
can also detect brief episodes of “non-optimal” microbiota (e.g. during menses)24 that 
may not cause significant genital inflammation and/or increase HIV risk and it is likely 
that more broadly, these communities may be dynamic, dependent upon a number of 
host and environmental factors (e.g. genital hygiene practices, sexual behavior, co-
morbidities, etc.). Therefore the duration and frequency of “non-optimal” vaginal 
microbiota is likely a critical factor requiring the incorporation of frequent sampling in 
longitudinal studies to better define the HIV risk associated with Nugent-BV and 
Molecular-BV.
Not all Lactobacillus spp. are associated with reduced genital inflammation and 
protection against HIV acquisition 
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Lactobacillus spp.-dominated cervicovaginal microbiota, and particularly with L. 
crispatus, are associated with a lack of genital inflammation relative to other bacterial 
communities.11,12,16,17  In a cross-sectional study, women with L. crispatus-dominated 
microbiota were less likely to be HIV positive compared to women with vaginal 
microbiota either dominated by L iners or depleted of Lactobacillus spp.40  Furthermore, 
HIV was associated with a high bacterial load and abundance of strict and facultative 
anaerobes.40  While this cross-sectional analysis could be due to reverse causation (i.e. 
HIV could cause microbiome differences), this observation is supported by a 
prospective study in South African adolescent girls where L. crispatus-dominated 
cervicovaginal microbiota, but not L. iners, was associated with a decreased risk of 
acquiring HIV.17  Additionally, L. iners was shown to be mildly inflammatory in in vitro 
co-cultures with vaginal epithelial cells.17   Thus while some Lactobacillus spp. are 
associated with decreased genital inflammation and HIV risk, not all Lactobacillus spp. 
are equally protective. 
The difference in the ability of distinct Lactobacillus spp. to provide protection against 
HIV may be due to several factors that include their ability to produce lactic acid that is 
responsible for acidifying the vagina to a low pH.25,41-43  Lactic acid has been shown to 
have antimicrobial and immune modulatory properties.44-47  Modulation of inflammatory 
responses by Lactobacillus spp. may also be influenced by differences in cell wall 
properties between strains.48,49  Another factor is the apparent lower temporal stability 
of L. iners-dominated microbiota compared to L. crispatus-dominated microbiota. 
Indeed, when exposed to extrinsic and intrinsic factors, L. iners-dominated vaginal 
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microbiota often transition to bacterial communities lacking Lactobacillus spp. and 
comprising a wide array of strict and facultative anaerobes.24,50  It is important to note 
that there is likely to be strain differences among Lactobacillus spp. (including L. 
crispatus) with levels of genital inflammation (Chetwin et al., Sci Reports, in press) as 
well as G. vaginalis clades and HIV risk, which cannot be resolved by Nugent scoring or 
current 16S rRNA gene sequencing or qPCR approaches.
Asymptomatic Nugent-BV or Molecular-BV is still associated with genital 
inflammation 
There is considerable controversy in the field regarding asymptomatic cases that lack 
Lactobacillus spp. as these appear disease free but may retain elevated risk of adverse 
health outcomes. Women who do not report any symptoms of BV but are positive for 
either Nugent- or Molecular-BV can still have “asymptomatic BV”35,51, a state often 
associated with cervicovaginal microbiota dominated by G. vaginalis (e.g. CT3, Table 
1)17,24 or are polymicrobial comprising facultative and/or obligate anerobes while lacking 
Lactobacillus spp. often described as community state type IV (CST-IV)25, CT417 or 
compositional subtype 1 (C1)12,52 (Table 1). However, BV, including asymptomatic 
Molecular-BV or Nugent-BV is often observed in African and Hispanic women17,25,28,51 
suggesting that genetic, socioeconomic, cultural or behavioural factors might play a role 
alone or in combination. Further, report of symptoms is subjective and var es between 
women since these may be “normal” if a woman has had them her entire adult life.  Yet 
her risk of HIV infection and other sexual and reproductive health outcomes may still be 
elevated due to asymptomatic Nugent-BV or Molecular-BV.  In Gosmann et al., the 
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majority of women who acquired HIV were asymptomatic and negative for Nugent-BV, 
despite having evidence of Molecular-BV.17   Thus, reliance on symptoms alone is not 
recommended for assessing increased risk for HIV. In the future, if methods to positively 
and effectively alter the microbiota are achieved, screening asymptomatic women in 
clinical practice may also be appropriate.
Terminology, definitions and recommendations
We list terminologies often used in the cervicovaginal microbiome field and provide 
definitions as a guide for investigators to promote precision and consistency (Box 1, 
Tables 1 and 2). We also propose the following recommendations for the field to 
consider.
1. There is a preferred consensus developing around the term “optimal” to describe 
cervicovaginal microbiota often associated with favourable health outcomes and 
characterized by a lack of symptoms, dominance of non-L. iners Lactobacillus 
spp. and a lack of genital inflammation. “Non-optimal” is preferred to describe 
microbiota-associated with adverse sexual and reproductive health outcomes, 
including increased HIV acquisition risk (Figure 1). 
2. Avoid use of the terms “dysbiotic” or “abnormal” microbiota, since both of these 
terms imply divergence from a normal state that might not exist for all women. 
For women with asymptomatic BV and low levels of genital inflammation, their 
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microbial community might represent their “normal” microbial state and these 
terms may inappropriately stigmatize these women.
3. We suggest that descriptive terms to describe the microbiota (i.e. in 
recommendations 1 and 2) should be tested for acceptability with women in 
qualitative studies such that terminology is friendly to women who may be likely 
to benefit from the development of approaches to reverse the consequences of 
Molecular-BV.
4. We propose new terminology that specifies the method used to diagnose BV i.e. 
Amsel-BV (based on Amsel criteria), Nugent-BV (defined by Nugent score), 
Molecular-BV (based on molecular methods), with subcategories defining the 
molecular technique employed i.e. Seq-BV or qPCR-BV (Box 1). Appropriate 
abbreviations could also be used for “non- ptimal” microbiota identified through 
new and emerging technologies including metagenomics, transcriptomics, 
metabolomics and metaproteomics.  
5. Amsel-BV, Nugent-BV and Molecular-BV can be further delineated into 
symptomatic or asymptomatic. Studies based on stratification of symptomatic BV 
is not recommended, given that “symptoms” can be subjective and do not fully 
capture the cervicovaginal microbiota associated with important health outcomes.
Page 19 of 40
Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801
AIDS Research and Human Retroviruses
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only; Not for Distribution
19
6. Not all “non-optimal” microbiota are “highly diverse” i.e. G. vaginalis-dominated 
microbiota (e.g. CT3, CST-IVB)11,17,24 25, which has also been referred to as “low 
diversity anaerobic dysbiosis” as distinct from “high diversity anaerobic dysbiosis” 
such as CT4 and CST-IVC.35  However, it is important to be precise when using 
the term “diverse” to describe microbiota. The use of the term “diverse” can be 
ambiguous with respect to 16S rRNA gene sequencing data. It is often used to 
describe communities such as CT4 and CST-IVC that have “species richness” 
i.e. many different species in a microbial ecosystem and “evenness” i.e. not 
dominated by particular species. However, it is possible that a community 
dominated by L. crispatus (e.g. CT1, CST-I, C2) can have high within community 
intraspecies diversity (Ravel unpublished). In addition, “L. crispatus-dominated” 
microbiota could also be diverse, as a result of diversity due to very low 
abundance taxa representing less than 1% of the community (i.e. an uneven 
community). 
7. When describing Lactobacillus spp. as “optimal” or “beneficial”, specify the 
Lactobacillus species. Not all Lactobacillus spp. or strains make ‘optimal’ 
cervicovaginal microbiota. Current data indicates that most strains of L. iners are 
less stable24, associated with increased genital inflammation17, and encodes 
factors that may be harmful to the vaginal mucosa.53,54 
8. We propose terminology that describes cervicovaginal microbiota associated with 
genital inflammation (MAGI) and microbiota associated with HIV acquisition 
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(MAHA). While the focus of this Perspectives article is on BV, these terms would 
also encompass STIs, pathobionts and VVC.  Use of these terminologies, 
including “susceptible” for HIV requires that there is evidence that the 
cervicovaginal microbiota increases genital inflammation (MAGI) and/or HIV risk 
(MAHA). These are overlapping but distinct microbiota-associated phenotypes 
(Figure 1).
9. There is a need for standardisation of methodology and terminology for 
characterising bacterial communities by 16S rRNA gene sequencing (e.g CSTs, 
CTs, Cs) defined by clustering analysis preferably compared to a reference 
database comprising a large number of cervicovaginal microbiota to avoid 
collapsing of distinct clusters due to low numbers of samples being analysed. 
Such a database (data from 12,000 samples) has been established by Jacques 
Ravel, which will be made available for use (unpublished). Other areas of 
standardisation are sample site (e.g. vaginal, cervical, lavage), sample 
processing and the use of primers directed to the same 16S rRNA gene region 
for amplification.
10.More frequent sampling of cervicovaginal microbiota is recommended when 
determining the association of a cervicovaginal microbiota states w th adverse 
health outcomes as well as more rigorous controlling of confounders that are 
associated with genital inflammation including STIs and VVC.
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12. Advance scientific knowledge into the mechanisms that underpin epidemiological
associations observed with distinct microbial communities and HIV risk that is 
critical for driving the development of viable treatment and prevention modalities 
to promote an optimal microbiota and prevent HIV. Develop better tissue and 
animal models that recapitulate the FRT and can be colonised with women's 
cervicovaginal microbiota and infected with HIV.
Conclusions.
Regardless of how it is defined, it is clear that BV is a topic of growing interest and 
importance for sexual and reproductive health in women. To facilitate making sense of 
this expanding research effort, we propose to use standardized definitions that “best 
capture genital inflammation and/or HIV/STI risk”. On this basis molecular methods for 
characterizing the cervicovaginal microbiota are anticipated to replace both Nugent and 
Amsel as a BV gold standard. This does not imply that Nugent and Amsel no longer 
have a role in assessing clinical BV. In clinical practice, Amsel will remain useful for 
diagnosing symptomatic BV; however, new sensitive and specific molecular diagnostic 
tests are becoming available such as the FDA approved BD MAX vaginal panel.33 34  
Many properly trained sites may opt to continue use of Nugent-BV due to cost or 
logistical reasons since there is a plethora of data published on Nugent-BV and it is 
known to capture a proportion of individuals colonised with abundance of non-
Lactobacillus-dominated bacterial communities with high specificity. However, to really 
understand the role of the non-optimal cervicovaginal microbiota in HIV and 
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inflammation, it will be necessary to employ a range of “omic” techniques including 
metagenomics (next generation DNA sequencing of whole bacteria, not only the 16S 
rRNA gene), transcriptomics, proteomics, and metabolomics in conjunction with 
immunological measurements. Use of these techniques will be necessary to advance 
our knowledge of BV and conditions that promote BV so that better treatments can be 
developed and to stop the cycle of frequent recurrence that is commonplace with 
current treatments. 
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Figure 1. Microbial causes of genital inflammation and/or altered HIV susceptibility. 
Each microbial class can cause inflammation independently or in combination with other 
microbes that may also be present in the same women. Strategies to mitigate as many 
of these causes as possible may be key to achieving the optimal FRT mucosa 
associated with positive health outcomes including protection against HIV infection. 
Optimal, cervicovaginal microbiota associated with no vaginal symptoms, lack of genital 
inflammation and decreased HIV risk; non-optimal, cervicovaginal microbiota associated 
with vaginal symptoms and/or genital inflammation and/or increased HIV risk; MAHA, 
microbiota associated with HIV acquisition; GI, genital inflammation; MAGI, microbiota 
associated with genital inflammation; BV, bacterial vaginosis; STIs, sexually transmitted 
infections; pathobionts, a symbiotic organism under normal circumstances that can 
become pathogenic e.g. Proteobacteria, Streptococci, Staphylococci or Enterococci 
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spp.; VVC, vulvovaginal candidiasis; ?, Lactobacillus spp. (e.g. L. iners) or strains that 
may not be optimal.
Figure 2. The “clinical iceberg” concept of adverse health outcomes, applied to BV. 
With better molecular methods we now appreciate that clinically evident BV, as 
diagnosed by a technique like Amsel’s criteria (Amsel-BV), does not capture a high 
proportion of women diagnosed with BV by Nugent (Nugent-BV) or by using molecular 
methods (Molecular-BV) that contributes to adverse sexual and reproductive health 
outcomes including increased HIV risk. Not all Amsel-BV positive samples are Nugent-
BV or Molecular-BV positive with this lack of overlap denoted by the red vertical line.
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Table 1. Classification of Cervicovaginal Bacterial Communities Determined 
by 16S rRNA Gene Sequencing
Abbreviation Definition Molecular-BV  
(Seq-BV)
CST-I L. crispatus dominated NO
CST-II L. gasseri dominated NO
CST-III L. iners dominated NO
CST-IVA Modest Lactobacillus spp. higher 
relative abundance of facultative 
and/or obligate anaerobes, BVAB1 
and G. vaginalis
YES
CST-IVB Modest Lactobacillus spp. higher 
relative abundance of facultative 
and/or obligate anaerobes, G. 
vaginalis and Atopobium vaginae
YES
CST-IVC Lacking Lactobacillus spp. and more 
even in anaerobe composition (i.e. 
no bacteria dominates) comprising 
Prevotella among others, as well as 
Anaerococcus, Finegoldia, 
Corynebacterium, Peptoniphilus, 
Megasphaera, Gemella spp.
YES
CST-V L. jensenii dominated NO
CT1 L. crispatus dominated NO
CT2 L. iners dominated NO
CT3 Depleted of Lactobacillus spp. and 
G. vaginalis-predominated
YES
CT4 Depleted Lactobacillus spp. and 
polymicrobial with a higher relative 
abundance of facultative and/or 
obligate anaerobes comprising 
Prevotella, Gardnerella, BVAB1, 
Sneathia and Megasphera spp.
YES
C1 Depleted of Lactobacillus spp. and 
polymicrobial with a higher relative 
abundance of facultative and/or 
obligate anaerobes
YES
C2 L. crispatus dominated NO
C3 L. iners dominated NO
Molecular-BV, bacterial vaginosis determined by characterising vaginal or 
cervical samples using molecular methods; Seq-BV, BV as determined by 
16S rRNA gene sequencing; CST, community state type24,25 ; CT, 
cervicotype11,17; C, compositional subtype12,52 
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Table 2.  Descriptive terms for cerviovaginal microbiota
Terms for Optimal Microbiota                                                                       Definition
Optimal  Microbiota associated with no vaginal symptoms, lack of genital inflammation and favourable 
sexual and reproductive health outcomes, including decrease risk of HIV acquisition
Eubiosis Microbiota that are “optimal”
Healthy Microbiota that are “optimal”
Normal Often used to describe “optimal” microbiota; less preferred terminology since “normal” is difficult to 
define
Lactobacillus dominant  (LD) Microbiota dominated by Lactobacillus spp. usually determined by 16S rRNA gene sequencing
Beneficial lactobacilli Optimal Lactobacillus spp , often used to distinguish L. crispatus (optimal) from L. iners
Protective Microbiota that protects against adverse health outcomes such as HIV.  Evidence of in vivo 
protection is required
Non-BV Microbiota composed of bacteria not consistent with bacterial vaginosis
Microflora Outdated terminology that should not be used to describe microbiota. Suggests that microbiota 
are composed of plants rather than bacteria, fungi, viruses, archea, protists.
Terms for Non-Optimal Microbiota
Non-optimal Microbiota associated with vaginal symptoms, and/or genital inflammation and/or adverse sexual 
and reproductive health outcomes including increased risk of HIV acquisition
Dysbiosis Imbalance in the microbiota or impaired microbiota or “non-optimal” microbiota. Avoid using this 
terminology for women with asymptomatic BV and low levels of genital inflammation as their 
microbiota might represent their “normal” state and may inappropriately be stigmatizing
Low diversity anaerobic 
dysbiosis
G. vaginalis or A. vaginae dominated microbiota associated with adverse sexual and reproductive 
health outcomes
High diversity anaerobic 
dysbiosis
Polymicrobial community depleted of Lactobacillus spp. associated with adverse sexual and 
reproductive health outcomes
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Harmful Less preferred terminology for microbiota associated with vaginal symptoms, genital inflammation, 
and/or an increased risk of adverse sexual and reproductive health outcomes
Non-Lactobacillus dominant 
(Non-LD)
Non-lactobacillus spp. dominated bacterial community
Polymicrobial Multiple bacterial species usually depleted of Lactobacillus spp. with an increase in obligate and/or 
facultative anaerobes.
Diverse Used to describe microbial communities comprising multiple bacterial species in the ecosystem. 
Needs to be defined since meaning can be ambiguous with respect to 16S rRNA gene 
sequencing.
Susceptible Microbiota associated with increased risk of HIV and other STIs or adverse reproductive health 
outcomes. Requires evidence to link microbiota to adverse health outcomes.
MAGI Microbiome associated with genital inflammation. This term can also encompass STIs and other 
microbes associated with genital inflammation including Candida spp. Requires evidence linking 
microbiota to genital inflammation
MAHA Microbiome associated with HIV acquisition. This term can also encompass STIs and other 
microbes associated with genital inflammation including Candida spp. Requires evidence linking 
microbiota to increased HIV risk
Pathobionts
Symbiotic organism under normal circumstances that becomes pathogenic e.g. Proteobacteria, 
Streptococci, Staphylococci or Enterococci spp. 
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Box 1. Proposed definitions for bacterial vaginosis (BV) based on traditional methods 
for BV diagnosis (Amsel and Nugent) and molecular techniques.
Figure 1. Microbial causes of genital inflammation and/or altered HIV susceptibility. 
Each microbial class can cause inflammation independently or in combination with other 
microorganismsbes that may also be present in the same women. Strategies to mitigate 
as many of these causes as possible may be key to achieving the optimal FRT mucosa 
associated with positive health outcomes including protection against HIV infection. 
Optimal, cervicovaginal microbiota associated with no vaginal symptoms, lack of genital 
inflammation and decreased HIV risk; non-optimal, cervicovaginal microbiota associated 
with vaginal symptoms and/or genital inflammation and/or increased HIV risk; MAHA, 
microbiota associated with HIV acquisition; GI, genital inflammation; MAGI, microbiota 
associated with genital inflammation; BV, bacterial vaginosis; STIs, sexually transmitted 
infections; pathobionts, a symbiotic organism under normal circumstances that can 
become pathogenic e.g. Proteobacteria, Streptococci, Staphylococci or Enterococci 
spp.; VVC, vulvovaginal candidiasis; ?, Lactobacillus spp. (e.g. L. iners) or strains that 
may not be optimal.
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Figure 2. The “clinical iceberg” concept of adverse health outcomes, applied to BV. 
With better molecular methods we now appreciate that clinically evident BV, as 
diagnosed by a technique like Amsel’s criteria (Amsel-BV), does not capture a high 
proportion of women diagnosed with BV by Nugent (Nugent-BV) or by using molecular 
methods (Molecular-BV) that contributes to adverse sexual and reproductive health 
outcomes including increased HIV risk. Not all Amsel-BV positive samples are Nugent-
BV or Molecular-BV positive with this lack of overlap denoted by the red vertical line.
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Figure 1. Microbial causes of genital inflammation and/or altered HIV susceptibility. 
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Figure 2. The “clinical iceberg” concept of adverse health outcomes, applied to BV. 
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